Pharma Co. Impel's Ch. 11 Liquidation Plan Approved

By Ben Zigterman · April 1, 2024, 5:07 PM EDT

Migraine-drug maker Impel Pharmaceuticals received confirmation of its Chapter 11 liquidation plan on Monday after selling its assets and making changes to the plan's exculpation provisions in response to a U.S....

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Migraine-drug maker Impel Pharmaceuticals Inc. and one of its subsidiaries, Impel NeuroPharma Australia Pty Ltd., filed for bankruptcy in Texas, listing $126.9 million in debt and plans to sell itself as a going concern.

Case Number

23-bk-80016

Judge

Stacey G Jernigan

Venue

U.S. Bankruptcy Court for the Northern District of Texas

Capital Structure

View Full Scorecard

Related Sections

Case Information

Case Title

IPI Legacy Liquidation Co.

Case Number

8:23-bk-80016

Court

Texas Northern

Nature of Suit

Date Filed

December 19, 2023

Recent Articles By Ben